v3.25.2
Other Non-current Assets - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
payment
Jun. 30, 2024
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
payment
Jun. 30, 2025
USD ($)
payment
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
payment
Intangible Asset, Acquired, Finite-Lived [Line Items]              
Revenues $ 10,003 $ 20,099     $ 18,723 $ 32,152  
Number of guaranteed royalty payments | payment       8      
License agreement with Sunovion Pharmaceuticals, Inc.              
Intangible Asset, Acquired, Finite-Lived [Line Items]              
Minimum annual royalty receivable       $ 1,000      
Number of annual royalty payments receivable | payment 3       3   4
Mitsubishi Tanabe Pharma America, Inc And Haisco For Exarvan              
Intangible Asset, Acquired, Finite-Lived [Line Items]              
Sales commissions and fees           $ 191  
Royalty              
Intangible Asset, Acquired, Finite-Lived [Line Items]              
Revenues         $ 914   $ 1,008
Royalty | License agreement with Sunovion Pharmaceuticals, Inc.              
Intangible Asset, Acquired, Finite-Lived [Line Items]              
Revenues     $ 8,000 $ 8,000